Navigation Links
New Cancer “Growth Blocking Super Drug” Patents Filed

San Diego, CA (PRWEB) February 08, 2013

The pharmaceutical world has been racing for the cure for cancer for decades with what most experts agree is limited success. The current drugs are either so toxic and damaging to the body that many patients have to weigh the benefits of their use or the drugs are only designed to treat specific types of cancers and often only specific “strains” of specific cancers.

There is now an emerging world class sprinter in the race to create the “Super Drug” – Kalos Therapeutics. The “Super Drug” in the cancer world refers to a drug that may be used to treat multiple types of cancer and their various strains while avoiding the additional trauma often caused by chemotherapy, radiation and many of the current cancer drugs.

Kalos Therapeutics is an emerging biomedical company with the exclusive patent to develop the ANP (Atrial Natriuretic Peptide) family of peptides as a new mechanism for the treatment of cancer.

Kalos is pioneering an approach to cancer treatment by developing peptides made primarily in the heart, as a cytostatic therapeutic for treating aggressive cancers by engaging known pathway receptors more efficiently without the side effects associated with chemotherapeutic or small molecule compounds.

George Colberg, the CEO of Kalos Therapeutics, has amassed a who’s who dream team representing the best and brightest of the cancer and bio-tech worlds. More importantly is the fact that the team has the ability to think differently about what is the most effective way to treat cancer. It is that difference in thinking that appears to be producing a game changing cancer therapy.

Anti-Cancer Bio-technology

“Kalos has successfully leveraged the natural antiproliferative activity of the Atrial Natriuretic Peptide (ANP) family of peptides in our patented Kalos Motif (s) exhibiting never before seen anti-cancer growth properties” says CEO, George Colberg.

Kalos’ drug has demonstrated remarkably broad anti-cancer activity, including inhibition of pancreatic, lung, prostate, breast, ovarian, colon, and melanoma cells in culture and of pancreatic, breast, and lung cancer tumors in models of human cancer.

The strategy is simple – stop cancer growth at an early stage before it has the chance to proliferate and inflict the damage to the body that we all fear from cancer. Kalos and their legal teams have been very active in its patent filings both in the US and internationally.

About Kalos Therapeutics

Kalos Therapeutics is a biopharmaceutical company that develops and commercializes proprietary product candidates primarily for the treatment of cancer and age related diseases. The ANP family of peptides represents a portfolio from which many therapeutics can be developed addressing multiple indications within cancer, age related diseases and non-malignant hyper proliferative disorders.

More information can be found on Kalos' web site at

Kalos Therapeutics
Press Inquiries & Additional Information
Tiffany Ramsey – Press Liaison

Read the full story at

Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. University of Colorado Cancer Center Review Shows Long-term Side-effects of New, Targeted Therapies in Pediatric Cancer Patients
2. Transcreener Assays Highlighted for Challenging Microbial, Cancer and Epigenetic Drug Targets at SLAS 2013
3. Governor Cuomo Announces Continued Growth at Roswell Park Cancer Institute with Regional Economic Development Council Funding; RPCI Center for Personalized Medicine established with CTG (NASDAQ: CTGX) serving as its technology partner
4. Transition in cell type parallels treatment response, disease progression in breast cancer
5. Two University of Colorado Cancer Center Studies Show that Silibinin, Found in Milk Thistle, Protects Against UV-Induced Skin Cancer
6. Navigating Cancer Announces Jeff Oberlander as VP, Engineering
7. Tracking the Battle Against Breast Cancer With New Market Research
8. Caris Life Sciences Adds Next-Generation Sequencing to Enhance Evidence-Based Tumor Profiling Service for Cancer Patients
9. WaferGens MyDesign Open Platform Facilitates Rapid Development of a Proprietary Prostate Cancer Diagnostic Panel in the Lab of Dr. Arul Chinnaiyan at the University of Michigan Cancer Center
10. Touch Medical Media Splits From Touch Briefings, Launches a Series of Cutting Edge, Free to Access, Educational Resources and Signs an Updated Media Partnership With ECCO, The European CanCer Organisation Representing 60,000 Oncology Professionals
11. DelMar Pharmaceuticals Announces Acquisition and $5.4 Million Private Placement to Advance Novel Cancer Therapies
Post Your Comments:
(Date:11/27/2015)... November 27, 2015 ... popularity of companion diagnostics is one of ... market with pharmaceutical companies and diagnostic manufacturers ... tests. . --> ... report on global cancer biomarkers market spread ...
(Date:11/25/2015)... -- PharmAthene, Inc. (NYSE MKT: PIP) announced  today that its ... (Rights Plan) in an effort to preserve the value ... 382 of the Internal Revenue Code (Code). ... its NOLs could be substantially limited if the Company ... of the Code. In general, an ownership change occurs ...
(Date:11/25/2015)... Nov. 25, 2015  Neurocrine Biosciences, Inc. (Nasdaq: ... President and CEO of Neurocrine Biosciences, will be presenting ... New York . ... website approximately 5 minutes prior to the presentation to ... the presentation will be available on the website approximately ...
(Date:11/25/2015)... PORTLAND, Oregon , November 25, 2015 /PRNewswire/ ... Deep Market Research Report is a professional and ... Genomics industry.      (Logo: ... basic overview of the industry including definitions, classifications, ... analysis is provided for the international markets including ...
Breaking Biology Technology:
(Date:11/18/2015)... York , November 18, 2015 ... Research has published a new market report titled  Gesture ... Trends, and Forecast, 2015 - 2021. According to the report, ... 2014 and is anticipated to reach US$29.1 bn by ... 2021. North America dominated ...
(Date:11/17/2015)... , November 17, 2015 ... au 19 novembre  2015.  --> Paris ... --> DERMALOG, le leader de l,innovation biométrique, ... la fois passeports et empreintes sur la même surface ... les passeports et l,autre pour les empreintes digitales. Désormais, ...
(Date:11/17/2015)... SOUTH EASTON, Mass. , Nov. 17, 2015 /PRNewswire/ ... "Company"), a leader in the development and sale of ... to the worldwide life sciences industry, today announced it ... closing of its $5 million Private Placement (the "Offering"), ... Offering to $4,025,000.  One or more additional closings are ...
Breaking Biology News(10 mins):